Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.

Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.

Zhitong FinanceJul 10 03:46 ET

Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).

Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.

Zhitong FinanceJul 8 20:58 ET

Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).

On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.

Zhitong FinanceJul 7 19:05 ET

It May Be Possible That Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) CEO Compensation Could Get Bumped Up

Key Insights Jilin Province Huinan Changlong Bio-pharmacy to hold its Annual General Meeting on 28th of May CEO Hong Zhang's total compensation includes salary of CN¥273.0k The total compensation

Simply Wall StMay 21 18:24 ET

A record high! The total number of clinical trials exceeded 4,000 in 2023

According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.

Zhitong FinanceMay 20 02:49 ET

Jilin Changlong Pharmaceutical (08049) will pay a special dividend of 0.0625 yuan per share on July 16

Jilin Changlong Pharmaceutical (08049) announced that the company will pay a special dividend per share on July 16, 2024...

Zhitong FinanceApr 25 10:59 ET